Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Colorectal Cancer Treatments and Studies, Lung Cancer Treatments and Mutations, DNA Repair Mechanisms, and Cancer Genomics and Diagnostics.
WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer.
Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations
Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations.
Acidosis overrides molecular heterogeneity to shape therapeutically targetable metabolic phenotypes in colon cancers
TRPM8 levels determine tumor vulnerability to channel agonists.
A Deep Learning Approach for Tracking Colorectal Cancer-Derived Extracellular Vesicles in Colon and Lung Models.
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells.
Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial.
MCT1-dependent lactate recycling is a metabolic vulnerability in colorectal cancer cells upon acquired resistance to anti-EGFR targeted therapy
MCT1-dependent lactate recycling is a metabolic vulnerability in colorectal cancer cells upon acquired resistance to anti-EGFR targeted therapy.
Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification.
Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells.
Transcriptome-wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer.
Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients.
Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition.
Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer.
Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT).
Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient.
Data from Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer
Data from Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells
Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer
Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer.
Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study.
Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy
Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy.
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.
Preclinical models as patients' avatars for precision medicine in colorectal cancer: past and future challenges.
Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids.
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer